Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

Thiazolidinediones (TZDs), among which Rosiglitazone, are known agonists of the peroxisome-proliferator-activated receptor γ (PPARγ) commonly used for treatment of hyperglycemia. A recently published article describing a case report on a patient affected by Fibrodysplasia Ossificans Progressiva (FOP...

Descripción completa

Detalles Bibliográficos
Autores principales: Bocciardi, Renata, Ravazzolo, Roberto
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896849/
https://www.ncbi.nlm.nih.gov/pubmed/20613955
http://dx.doi.org/10.1155/2010/541927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896849/
https://www.ncbi.nlm.nih.gov/pubmed/20613955
http://dx.doi.org/10.1155/2010/541927

Ejemplares similares